MetLife, Inc. $MET Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. grew its stake in shares of MetLife, Inc. (NYSE:MET) by 40.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 386,782 shares of the financial services provider’s stock after purchasing an additional 112,270 shares during the quarter. Victory Capital Management Inc. owned 0.06% of MetLife worth $31,859,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Norges Bank purchased a new position in MetLife in the 2nd quarter worth approximately $756,104,000. Vanguard Group Inc. lifted its position in shares of MetLife by 13.3% during the third quarter. Vanguard Group Inc. now owns 64,749,521 shares of the financial services provider’s stock worth $5,333,418,000 after purchasing an additional 7,578,199 shares in the last quarter. ABN AMRO Bank N.V. purchased a new position in shares of MetLife in the second quarter valued at $178,669,000. Amundi grew its holdings in MetLife by 40.2% during the 2nd quarter. Amundi now owns 4,507,362 shares of the financial services provider’s stock valued at $361,265,000 after purchasing an additional 1,292,107 shares in the last quarter. Finally, Man Group plc increased its stake in MetLife by 325.5% during the 2nd quarter. Man Group plc now owns 1,344,551 shares of the financial services provider’s stock worth $108,129,000 after buying an additional 1,028,554 shares during the period. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Wells Fargo & Company decreased their price objective on shares of MetLife from $97.00 to $93.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Evercore set a $95.00 price target on MetLife in a research note on Tuesday, February 10th. Keefe, Bruyette & Woods reduced their price target on MetLife from $92.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, November 11th. UBS Group lifted their price objective on MetLife from $94.00 to $98.00 and gave the stock a “buy” rating in a report on Thursday, February 5th. Finally, Morgan Stanley reduced their target price on MetLife from $101.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $94.18.

MetLife News Summary

Here are the key news stories impacting MetLife this week:

• Positive Sentiment: MetLife confirmed its previously announced Q1 2026 dividend on its Series A floating-rate preferred shares, $0.31501229 per share, signaling consistency in capital returns for preferred holders and helping support yield-sensitive investors. Article Title
• Positive Sentiment: MetLife and partner Crow Holdings completed the sale/trade of 210 multifamily units in Tampa — an example of active portfolio management that can free capital or crystallize gains from real-estate holdings. Article Title
• Neutral Sentiment: MetLife GCC leased ~75,000 sq ft in Noida’s Oxygen Business Park — a regional expansion/lease that speaks to business presence in India but is unlikely to move the stock materially in the near term. Article Title
• Neutral Sentiment: High-profile events at MetLife Stadium (temporary renaming/World Cup hosting coverage, ticket guides) increase brand visibility and venue revenue potential, but these items are peripheral to core insurance fundamentals. Article Title
• Neutral Sentiment: A recent piece comparing MetLife’s stock performance to peers provides context for relative valuation and momentum; useful for investors but not a direct catalyst. Article Title
• Negative Sentiment: Morgan Stanley published a pessimistic forecast for MET, which likely contributed to selling pressure and the intraday decline — analyst downgrades/price-target cuts are common drivers of short-term stock weakness. Article Title

MetLife Trading Down 1.5%

NYSE:MET opened at $71.83 on Monday. The company has a market cap of $46.84 billion, a PE ratio of 15.28, a P/E/G ratio of 0.66 and a beta of 0.76. The business’s 50 day moving average is $77.20 and its two-hundred day moving average is $78.72. The company has a quick ratio of 0.20, a current ratio of 0.20 and a debt-to-equity ratio of 0.52. MetLife, Inc. has a 52 week low of $65.21 and a 52 week high of $85.00.

MetLife (NYSE:MET) last posted its quarterly earnings results on Wednesday, February 4th. The financial services provider reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.34 by $0.15. MetLife had a return on equity of 21.81% and a net margin of 4.38%.The business had revenue of $52.44 billion for the quarter, compared to analyst estimates of $31.43 billion. During the same period in the prior year, the company posted $2.08 EPS. The business’s revenue was up 27.6% compared to the same quarter last year. On average, analysts predict that MetLife, Inc. will post 9.65 EPS for the current year.

MetLife Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 3rd will be issued a dividend of $0.5675 per share. This represents a $2.27 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Tuesday, February 3rd. MetLife’s dividend payout ratio is 48.30%.

MetLife Company Profile

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.